Eurolyser Diagnostics - Premium Laboratory Equipment

Eurolyser smart appointed as point of care test instrument for world wide Ferritin study

Thursday, 30. September 2010

At 250 sites world wide the Eurolyser smart 546 was selected to perform patient near testing for an open-label, multicentre, randomised, 3-arm study. It is to investigate the comparative efficacy and safety of intravenous ferric carboxymaltose versus oral iron for the treatment of iron deficiency anaemia in subjects with non-dialysis-dependent chronic kidney disease.

“We are very proud of being part of such an important study. This is jet another proof ot the reliability and flexibility of the Eurolyser smart point of care system” says Gerhard Bonecker, CEO of Eurolyser Diagnostica.

Besides clincal studies, the unique platform is used by general practitioners, diabetes centers, angiologists, emgergency labs, cardiologists, gynecologists, pediatricians, blood donation centers and anti-aging physicians. Tests available for the instrument include CRP, hsCRP, INR (PT), Homocystein, Lipoprotein(a), D-Dimer, ĀµAlbumin, Haemoglobin and – as mentioned above -Ferritin.

“This easy-to-operate analyzer is a worthwhile investment for every user, thanks to its great flexibility and constantly expanding test protfolio” remarks Mike Gruber, MD of Eurolyser Diagnostica. “We are about to launch a fully quantitative FOB (faecal occult blood) test, which will further enhance the test menue” he ads with a smile

Eurolyser News

18. August 2020

SDMA: A new veterinary assay for evaluation of chronic kidney diseases...
» Read more...

17. August 2020

Phenobarbital: A next generation epilepsy monitoring assay...
» Read more...

10. December 2019

Launch of bidirectional connectivity: a feature for CUBE series instruments...
» Read more...

5. December 2019

Eurolyser is now ISO 13485:2016 certified...
» Read more...